HIF‐1α and PD‐L1 as Predictive Efficacy Marker for Neoadjuvant Chemoradiotherapy in Rectal Cancer

Key Points

• The aim is to evaluate HIF-1α and PD-L1 as markers for predicting the effectiveness of neoadjuvant chemoradiotherapy in rectal cancer.
• Assessed HIF-1α and PD-L1 expression levels in rectal cancer samples.
• Correlated these markers with treatment outcomes and patient prognosis.
• Utilized statistical methods for data analysis to determine significance.
• Increased HIF-1α and PD-L1 levels were associated with lower treatment efficacy.
• Patients with high HIF-1α and PD-L1 expression had worse prognoses.
• These markers provide reliable predictive insights for patient outcomes in treatment.